RESUMEN
The MRL lpr/lpr mouse strain is an animal model for the autoimmune disorder systemic lupus erythematosus (SLE). Pathologic changes in the mice include a severe proliferative glomerulonephritis, lymph node and spleen enlargement, increase in autoantibody titers, and shortened life spans. In the present investigation, female MRL lpr/lpr mice have been dosed po daily for 7 months with the selective estrogen receptor modulator (SERM) LY139478 (4 mg/kg) or 17alpha-ethinylestradiol (EE2, 1 mg/kg) and compared to vehicle control animals. The LY139478 group had an increase in survival (73% survival at 7 months, P = 0.02) but the EE2-treated animals did not (53% survival at 7 months, P = 0.4) when compared to the control group (32% survival at 7 months). Although there were no reductions in autoantibody levels as determined by anti-DNA antibody ELISA, histological analysis of kidney tissue indicated that both LY139478 and EE2 mitigated the progression of glomerular nephritis which was evident in the controls. In contrast, there were no significant differences in lymph node size although the LY139478 and EE2 groups retained a well-defined sinusoidal region. Finally, flow cytometric analysis documented that thymuses from animals treated for 7 months with LY139478 but not with EE2 contained predominantly CD4+/CD+ T cells consistent with a normal thymic phenotype observed in non-MRL lpr/lpr mouse strains. These studies demonstrate that SERMs may be potentially useful for the treatment of autoimmune disorders.
Asunto(s)
Congéneres del Estradiol/farmacología , Antagonistas de Estrógenos/farmacología , Etinilestradiol/farmacología , Lupus Eritematoso Sistémico/tratamiento farmacológico , Lupus Eritematoso Sistémico/inmunología , Pirrolidinas/farmacología , Receptores de Estrógenos/inmunología , Tiofenos/farmacología , Animales , Enfermedades Autoinmunes , Linfocitos T CD4-Positivos/clasificación , Linfocitos T CD8-positivos/clasificación , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Antagonistas de Estrógenos/química , Femenino , Riñón/patología , Lupus Eritematoso Sistémico/mortalidad , Lupus Eritematoso Sistémico/patología , Ganglios Linfáticos/patología , Ratones , Ratones Endogámicos MRL lpr , Estructura Molecular , Pirrolidinas/química , Tiofenos/química , Timo/citologíaRESUMEN
A new series of sterols was synthesized and tested in a CHO cell-based LDL receptor/luciferase (LDLR/Luc) assay to investigate the capability of derepressing the transcription of LDL receptor promoter in the presence of 25-hydroxycholesterol. The effect of various substitutions on antagonizing the repressing effect mediated by 25-hydroxycholesterol was also studied in terms of regio- and stereochemistry, lipophilicity, steric bulk, and pi-electron density. Except 12, compounds active in the primary LDLR/Luc assay were not active in the secondary simian virus 40/luciferase (SV40/Luc) assay, demonstrating the specificity of their in vitro activity. Eight active compounds of various structural types were selected and screened in a [1-14C-acetate]cholesterol biosynthesis inhibition assay; none has shown any interference with the cholesterol biosynthesis in CHO cells. In hypercholesterolemic hamsters, generally, compounds that were active in vitro were active in vivo and vice versa, with the exception of three in vitro inactive compounds: 3 beta-ols 3a' and 3c' as well as 3-ketone 2a. Experimental results from the livers of hamsters revealed that the in vivo conversion of 3a' or 2a to 3a has in part contributed to the observed in vivo activity, and it is also anticipated that 3c' may similarly be converted to 3c in hamsters.
Asunto(s)
Anticolesterolemiantes , Receptores de LDL/genética , Esteroles/síntesis química , Esteroles/farmacología , Animales , Células CHO , Cricetinae , Hidroxicolesteroles/farmacología , Lovastatina , Mesocricetus , Regiones Promotoras Genéticas , Transcripción Genética/efectos de los fármacosRESUMEN
The effects of cholesteryl ester transfer protein (CETP) inhibition on the serum lipoprotein profile in both normocholesterolemic and hypercholesterolemic hamsters has been determined following subcutaneous injection of 12.5 mg/kg of the CETP neutralizing monoclonal antibody, TP2. Inhibition of CETP activity was greater than 60% and resulted in a 30-40% increase in high density lipoprotein (HDL) in both normal and hypercholesterolemic animals. These HDL effects were observed 1 day post-injection, were maximal by 4 days, and returned to control values by 14 days. Inhibition of CETP activity resulted in a decrease in both low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol concomitant with HDL increase, and in hypercholesterolemic animals resulted in increased total serum cholesterol. In addition to the quantitative differences in LDL and HDL, there were significant increases in the size of the HDL, a shift to smaller LDL particles, and changes in apolipoprotein (apo) composition as evaluated by FPLC and Western blot analysis. Large apoA-I-poor and apoE-containing HDL became prevalent in hypercholesterolemic hamsters after CETP inhibition. In addition, the size of the CETP-containing HDL particles increased with inhibition of transfer activity. While these effects were apparent in normocholesterolemic animals, the changes in apolipoprotein distribution and HDL subspecies as detected on native gels were more significant in the hypercholesterolemic animals. The changes in the HDL profile and apolipoprotein distribution after CETP inhibition in hamsters were similar to those reported in CETP-deficient Japanese subjects, suggesting the utility of the hypercholesterolemic hamster as an in vivo model for the understanding of the lipoprotein changes associated with CETP inhibition.
Asunto(s)
Apolipoproteínas/sangre , Proteínas Portadoras/antagonistas & inhibidores , Glicoproteínas , Hipercolesterolemia/sangre , Lipoproteínas HDL/sangre , Animales , Anticuerpos Monoclonales/administración & dosificación , Proteínas Portadoras/inmunología , Colesterol/sangre , Proteínas de Transferencia de Ésteres de Colesterol , Ésteres del Colesterol/sangre , HDL-Colesterol/sangre , LDL-Colesterol/sangre , VLDL-Colesterol/sangre , Cricetinae , Modelos Animales de Enfermedad , Humanos , Lipoproteínas HDL/clasificación , Masculino , Mesocricetus , Pruebas de NeutralizaciónRESUMEN
Preclinical efficacy studies are presented in a human ovarian carcinoma model utilizing several novel conjugation strategies with the KS1/4 monoclonal antibody and derivatives of the vinca alkaloid desacetylvinblastine hydrazide. The chemoimmunoconjugates KS1/4-beta-alanine-methylenemalonic acid ethyl ester-4-decacetylvinblastine 23-hydrazide (KS1/4-BAMME-DAVLB-HY), KS1/4-beta-alanine-5-formylpyrrole-2-carboxylic acid-4-desacetylvinblastine 23-hydrazide (KS1/4-BAP-DAVLB-HY), and KS1/4-4-desacetylvinblastine 23-hydrazide were explored in the OVCAR-3 human ovarian carcinoma xenograft model. These conjugates, constructed with variable linker stability between the vinca alkaloid and the antibody, were studied by comparing the route of administration and the treatment schedule. Under these conditions a mean survival time from 28 to 35 days in untreated control animals was observed. Significant increases in survival (i.e. 3-9-fold over untreated control animals) were observed with all the immunoconjugates tested but with varying potency and efficacy dependent on linker strategy. Parallel therapy with equivalent doses of free DAVLB-HY or a non-antigen-binding immunoconjugate did not significantly increase the survival of the animals. These results suggest several chemoimmunoconjugate strategies for site-directed therapy of human ovarian cancer.
Asunto(s)
Anticuerpos Monoclonales , Inmunotoxinas/uso terapéutico , Neoplasias Ováricas/tratamiento farmacológico , Vinblastina/análogos & derivados , Adenocarcinoma/patología , Animales , Anticuerpos Monoclonales/química , Muerte Celular/efectos de los fármacos , Estabilidad de Medicamentos , Femenino , Humanos , Inmunotoxinas/administración & dosificación , Ratones , Ratones Desnudos , Estructura Molecular , Trasplante de Neoplasias , Neoplasias Ováricas/patología , Ratas , Células Tumorales Cultivadas , Vinblastina/administración & dosificación , Vinblastina/química , Vinblastina/uso terapéuticoRESUMEN
A conjugate of 4-desacetylvinblastine-3-carboxyhydrazide (DAVLBHY) and the glioma-reactive monoclonal antibody (mAb) 9.2.27 induced long-term suppression of tumor growth in athymic nude mice engrafted with U87MG human glioma cells. In vitro, DAVLBHY had the strongest antiproliferative activity (inhibitory concentration at which incorporation of [3H]thymidine is at 50% of untreated control is 2.0 x 10(-9) M) of seven cytotoxic drugs tested and so was chosen for conjugation to mAb 9.2.27, which reacts specifically with the core protein of chondroitin sulfate proteoglycans found in human glioblastomas. After conjugation of DAVLBHY to the carbohydrate residues of mAb 9.2.27 it retained its full binding capacity. For in vivo studies, DAVLBHY and several conjugate derivatives were evaluated by using two dosages of i.v. injections, each starting 2 days after s.c. tumor inoculation. The control tumors reached a volume of nearly 3000 mm3 within 30 days. Tumor growth was delayed by about 20 days with four i.v. injections of 0.5 mg/kg 9.2.27-DAVLBHY, which was slightly superior to the unconjugated drug. Moreover, 9.2.27-DAVLBHY produced a highly significant suppression of growth so that the average tumor volume was only 3% of that observed in untreated controls after 28 days. Four injections of this conjugate at a larger dose, 2.0 mg/kg, prevented recurrence of the tumors for 130 days in all animals tested, thus demonstrating a significant increase in the therapeutic index, since the unconjugated drug provided limited inhibition of tumor growth for only 40 days. The specificity of the antitumor effect was demonstrated in a comparison with the control conjugate, KS1/4-DAVLBHY, which despite partial tumor suppression had only a transient effect. The specific antitumor effect of 9.2.27-DAVLBHY was unexpected, since the target antigen is expressed at a relatively low density (40,000 sites/cell) on U87MG glioma cells.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Glioma/tratamiento farmacológico , Inmunotoxinas/uso terapéutico , Vinblastina/análogos & derivados , Animales , Anticuerpos Monoclonales/metabolismo , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Glioma/metabolismo , Humanos , Inmunotoxinas/metabolismo , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Células Tumorales Cultivadas , Vinblastina/metabolismo , Vinblastina/uso terapéuticoRESUMEN
The activity of the conjugate of monoclonal antibody KS1/4 with 4-desacetylvinblastine-3-carboxhydrazide (KS1/4-DAVLB-HY) was explored in the OVCAR-3 human ovarian xenograft tumor model. Multiple schedules of KS1/4-DAVLB-HY administration were employed, including a comparison of i.p. and i.v. routes of treatment. When inoculates of 6 x 10(7) OVCAR-3 cells were injected i.p. into female athymic nude mice, untreated control animals had a mean survival of 18-34 days, with the development of massive ascites and large intraabdominal tumors. Significant increases in survival were observed in KS1/4-DAVLB-HY conjugate-treated animals with all schedules utilized. Parallel therapy with equivalent doses of free DAVLB-HY or a non-antigen-binding immunoconjugate did not significantly increase the survival of the animals. These data demonstrate that the immunoconjugate KS1/4-DAVLB-HY significantly increases the survival of OVCAR-3 tumor-bearing mice and indicates that this immunoconjugate may be useful in the treatment of human ovarian cancer.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Inmunotoxinas/uso terapéutico , Neoplasias Ováricas/tratamiento farmacológico , Vinblastina/análogos & derivados , Animales , Ensayos de Selección de Medicamentos Antitumorales/métodos , Femenino , Humanos , Ratones , Ratones Desnudos , Neoplasias Ováricas/mortalidad , Células Tumorales Cultivadas , Vinblastina/metabolismo , Vinblastina/uso terapéuticoRESUMEN
A polyclonal antisera specific for human platelet thrombospondin (TSP) has been utilized to study the biosynthesis and secretion of TSP in the M21 human melanoma cell line. Pulse-chase indirect immunoprecipitation analysis reveal that human melanoma cells rapidly synthesize and secrete this platelet alpha-granule associated glycoprotein. Topographical analysis of the melanoma cell surface by indirect immunofluorescence indicate that the TSP molecules have no obvious extracellular organization. The implications of thrombospondin synthesis in the metastatic process of melanoma are discussed.
Asunto(s)
Melanoma Experimental/metabolismo , Glicoproteínas de Membrana/biosíntesis , Técnica del Anticuerpo Fluorescente , Humanos , Cinética , Glicoproteínas de Membrana/metabolismo , Pruebas de Precipitina , Trombospondinas , Células Tumorales CultivadasRESUMEN
A human adenocarcinoma-associated antigen (KSA) defined by the monoclonal antibody KS1/4 has become the focus of several site-directed strategies for tumor therapy. KSA, a 40,000 Da cell surface glycoprotein antigen, is found at a high density in all adenocarcinomas examined to date and in corresponding normal epithelial tissues. Here we describe the cloning and sequencing of overlapping complementary DNA clones which encode the entire KSA as expressed in UCLA-P3, a human lung adenocarcinoma cell line. We have deduced the 314-amino acid sequence and have compared it to the N-terminal amino acid sequence data of the affinity-purified antigen. The KSA is synthesized as a 314-residue-long preproprotein that is then processed to a 232-residue-long antigen. KSA appears to have a single transmembrane domain of 23 residues that separates the highly charged 26-residue cytoplasmic domain from the extracellular domain. The N-terminal region of the propeptide is rich in cysteines and contains three potential N-glycosylation sites. Computer-assisted analyses at both the DNA and protein levels have found no significant similarities of this protein to known sequences, but a GC-rich 5' terminus is evident. Northern blot analysis shows that transcription of KSA can be detected in RNA isolated from normal colon but not in RNA isolated from normal lung, prostate, or liver.
Asunto(s)
Antígenos de Neoplasias/genética , Moléculas de Adhesión Celular , Clonación Molecular , ADN/análisis , Secuencia de Aminoácidos , Antígenos de Neoplasias/análisis , Secuencia de Bases , Línea Celular , Colon/análisis , Molécula de Adhesión Celular Epitelial , Glicosilación , Humanos , Neoplasias Pulmonares/análisis , Datos de Secuencia Molecular , Peso Molecular , ARN/análisisRESUMEN
The human adenocarcinoma-associated antigen gp40 is a cell surface glycoprotein recognized by murine monoclonal antibody KS1/4. A KS1/4-Sepharose affinity matrix was utilized to purify gp40 from detergent lysates of either tissue culture cells or nude mouse xenograft tumors of the human lung adenocarcinoma cell line P3-UCLA. This single immunoaffinity chromatography step yielded an antigen preparation of approximately 95% purity which was further characterized by immunochemical and enzymatic techniques. The gp40 molecule was shown to have both complex and high-mannose oligosaccharides comprising some 16% of the apparent molecular weight. The antigen preparation was suitable for gas-phase N-terminal amino acid sequencing and the first 16 residues of the N-terminus were determined. Despite considerable molecular heterogeneity, gp40 shows a single N-terminal sequence.
Asunto(s)
Anticuerpos Monoclonales , Antígenos de Neoplasias/aislamiento & purificación , Glicoproteínas de Membrana/aislamiento & purificación , Secuencia de Aminoácidos , Antígenos de Neoplasias/análisis , Western Blotting , Electroforesis en Gel de Poliacrilamida , Humanos , Immunoblotting , Técnicas para Inmunoenzimas , Glicoproteínas de Membrana/análisis , Sefarosa , Células Tumorales CultivadasRESUMEN
The tissue and tumor distribution of the antigen recognized by monoclonal antibody KS1/4 was determined by a combination of immunoperoxidase techniques, flow cytometric analyses and solid phase enzyme-linked immunoassays. These data document that the KS1/4 antigen is expressed in many epithelial malignancies and normal epithelial surfaces suggesting that this antigen represents an epithelial/epithelial malignancy marker.
Asunto(s)
Anticuerpos Monoclonales , Antígenos de Neoplasias/inmunología , Biomarcadores de Tumor/inmunología , Anticuerpos Antineoplásicos/inmunología , Ensayo de Inmunoadsorción Enzimática , Epitelio/inmunología , Citometría de Flujo , Humanos , Técnicas para Inmunoenzimas , Distribución TisularAsunto(s)
Inmunotoxinas/uso terapéutico , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Alcaloides de la Vinca/uso terapéutico , Animales , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/aislamiento & purificación , Anticuerpos Monoclonales/uso terapéutico , Línea Celular , Supervivencia Celular/efectos de los fármacos , Humanos , Ratones , Ratones Desnudos , Trasplante Heterólogo , Alcaloides de la Vinca/administración & dosificación , Alcaloides de la Vinca/farmacologíaRESUMEN
The monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), and free 4-desacetylvinblastine (DAVLB) were administered i.v. to male athymic nude mice bearing P3/UCLA human lung adenocarcinoma tumors. Although the plasma pharmacokinetics were similar between LY256787 and DAVLB (terminal plasma half-lives of 62 and 83 hr, respectively), substantial differences in the volumes of distribution and initial redistribution-elimination phases were found. Uptake of LY256787 into tumor was apparent, with maximal radioequivalent concentrations measured 96 hr after dosing; no similar uptake was found after dosing with free DAVLB. The ratios of concentrations of drug radioequivalents in tumor to those in other tissues were generally greater than 1.0 when measured 24 to 48 hr after dosing with LY256787 but were less than 1.0 after free DAVLB. These data support the concept of site-specific delivery to the tumor tissue of the vinca alkaloid by the antibody. Plasma pharmacokinetics and tissue distribution were compared in males and females with a lower dose of LY256787. No sex-related differences in the plasma pharmacokinetics were found (terminal half-lives of 90 and 84 hr in males and females). Some sex-related biodistribution differences occurred. In all studies, the primary route of elimination was fecal. These studies suggest that the KS1/4 monoclonal antibody targets DAVLB to the P3/UCLA human lung adenocarcinoma in vivo in the human xenograft model and that an increased therapeutic index may be achieved with LY256787 over conventional free drug therapy.
Asunto(s)
Adenocarcinoma/metabolismo , Anticuerpos Monoclonales/metabolismo , Inmunotoxinas/metabolismo , Neoplasias Pulmonares/metabolismo , Vinblastina/análogos & derivados , Animales , Femenino , Semivida , Cinética , Masculino , Ratones , Ratones Desnudos , Neoplasias Experimentales/metabolismo , Factores Sexuales , Distribución Tisular , Vinblastina/metabolismoRESUMEN
Flow cytometric methods for the evaluation of the cell surface binding properties of monoclonal antibody (MoAb)-drug/toxin conjugates defining tumor-associated antigens are presented. In these techniques, suspension cultures of solid human tumor cell lines are incubated with either varying dilutions of MoAb or MoAb-drug conjugates followed by FITC-conjugated anti-mouse immunoglobulin antibodies in an indirect assay or with FITC-conjugated MoAbs specific for the tumor target cell line in a competition assay. The amount of fluorescent probe bound is measured by flow cytometry and the mean fluorescence intensity determined. The relative binding capacity is quantified by linear regression of the mean fluorescence versus the concentration of primary antibody or antibody conjugate. The application of these techniques to several drug and toxin conjugates of MoAb KS1/4, which defines a human adenocarcinoma-associated antigen, demonstrates that these assays can be effectively utilized to monitor the effects of covalent chemical modification on a MoAb's antigen binding reactivity.
Asunto(s)
Anticuerpos Monoclonales/metabolismo , Anticuerpos Antineoplásicos/metabolismo , Reacciones Antígeno-Anticuerpo , Antígenos de Neoplasias/inmunología , Citometría de Flujo/métodos , Inmunotoxinas/metabolismo , Adenocarcinoma/inmunología , Unión Competitiva , Línea Celular , Neoplasias Pulmonares/inmunologíaRESUMEN
Viridin B, a bacteriocin produced by Streptococcus mitis, copurified with the alpha-hemolysin after ammonium sulfate precipitation and gel filtration on Sephadex G-200. The bacteriocin and hemolysin were separated in some instances by ion-exchange chromatography on diethylaminoethyl-Sephadex A-50, but the two substances were shown to be distinct after polyacrylamide gel electrophoresis. Attempts at recovery of nonhemolytic or nonbacteriocinogenic mutants were unsuccessful after exposure to mutagenic agents. The molecular weight of viridin B was determined to be approximately 87,000.